Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Sammy Huygens, Bas Oude Munnink, Arvind Gharbharan, Marion Koopmans, Bart Rijnders
doi: https://doi.org/10.1101/2022.04.06.22273503
Sammy Huygens
1Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bas Oude Munnink
2Department of Viroscience, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arvind Gharbharan
1Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Koopmans
2Department of Viroscience, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart Rijnders
1Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: b.rijnders@erasmusmc.nl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain. It retains activity against the Omicron BA.1 variant and is used to treat immunocompromised patients as they are at increased risk for a severe outcome of COVID-19.

Methods We studied viral evolution in 47 immunocompromised patients infected with Omicron BA.1 or 2 and treated with sotrovimab. SARS-CoV-2 PCR was performed at baseline and weekly thereafter until Ct-value was ≥ 30. All RNA samples were sequenced to determine the variant and occurrence of mutations, in particular in the Spike protein, after treatment.

Results Twenty-four (51%) of the 47 patients were male and their median age was 63 years. Thirty-one (66%) had undergone a solid organ transplantation and 13 (28%) had received prior B-cell depleting therapy. Despite a history of vaccination, 24 of 30 patients with available data on anti-SARS-CoV-2 IgG Spike antibodies prior to treatment with sotrovimab had very low or no antibodies. Median time to viral clearance (Ct-value ≥ 30) after treatment was 15 days (IQR 7-22). However, viral RNA with low Ct-values was continuously detected for at least 28 days after treatment in four patients infected with BA.1. Mutations in the Spike protein at position 337 or 340 were observed in all four patients. Similar mutations were also found after treatment of two patients with a BA.2 infection but both cleared the virus within two weeks. Thus following treatment with sotrovimab, spike mutations associated with reduced in vitro susceptibility were detected in 6 of 47 (13%) patients.

Conclusion Viral evolution towards resistance against sotrovimab can explain treatment failure in most immunocompromised patients and these patients can remain infectious after treatment. Therefore, documenting viral clearance after treatment is recommended to avoid that these patients unintentionally become a source of new, sotrovimab resistant, variants. Research on direct acting antivirals and possibly combination therapy for the treatment of COVID-19 in immunocompromised patients is needed.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement numbers 874735 (VEO) and 101003589 (RECoVER) and from ZonMW under grant 10150062010005

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Erasmus Medical Center (Rotterdam)gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This work has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement numbers 874735 (VEO) and 101003589 (RECoVER) and from ZonMW under grant 10150062010005

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted April 06, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant
Sammy Huygens, Bas Oude Munnink, Arvind Gharbharan, Marion Koopmans, Bart Rijnders
medRxiv 2022.04.06.22273503; doi: https://doi.org/10.1101/2022.04.06.22273503
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant
Sammy Huygens, Bas Oude Munnink, Arvind Gharbharan, Marion Koopmans, Bart Rijnders
medRxiv 2022.04.06.22273503; doi: https://doi.org/10.1101/2022.04.06.22273503

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (182)
  • Allergy and Immunology (438)
  • Anesthesia (100)
  • Cardiovascular Medicine (960)
  • Dentistry and Oral Medicine (179)
  • Dermatology (112)
  • Emergency Medicine (261)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (426)
  • Epidemiology (9082)
  • Forensic Medicine (5)
  • Gastroenterology (427)
  • Genetic and Genomic Medicine (1991)
  • Geriatric Medicine (195)
  • Health Economics (409)
  • Health Informatics (1345)
  • Health Policy (665)
  • Health Systems and Quality Improvement (532)
  • Hematology (214)
  • HIV/AIDS (428)
  • Infectious Diseases (except HIV/AIDS) (10911)
  • Intensive Care and Critical Care Medicine (578)
  • Medical Education (202)
  • Medical Ethics (55)
  • Nephrology (225)
  • Neurology (1868)
  • Nursing (110)
  • Nutrition (276)
  • Obstetrics and Gynecology (365)
  • Occupational and Environmental Health (474)
  • Oncology (1014)
  • Ophthalmology (308)
  • Orthopedics (111)
  • Otolaryngology (186)
  • Pain Medicine (128)
  • Palliative Medicine (45)
  • Pathology (268)
  • Pediatrics (591)
  • Pharmacology and Therapeutics (279)
  • Primary Care Research (237)
  • Psychiatry and Clinical Psychology (1928)
  • Public and Global Health (4175)
  • Radiology and Imaging (687)
  • Rehabilitation Medicine and Physical Therapy (375)
  • Respiratory Medicine (555)
  • Rheumatology (229)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (210)
  • Toxicology (39)
  • Transplantation (111)
  • Urology (82)